Sari la conținut

Română · beta. Traducerea a fost făcută automat și este încă în curs de revizuire. Citește pagina în engleză

perspectiva aiqbenchMachine learning

analiza aiqbench

This study applies a cost-sensitive XGBoost model to predict ESBL phenotypes in Enterobacteriaceae using pre-culture EHR data, aiming to optimize empiric antibiotic selection across 12 hospitals. The research demonstrates that prior colonization history is the strongest predictor and shows that removing socioeconomic features like neighborhood deprivation maintains model performance, supporting equitable clinical deployment. While the application involves significant medical impact, the core technical contribution lies in machine learning model development and validation for a specific clinical decision problem.
Sursă care acoperăarXiv
Ce este aceastaLectura unui model asupra articolului și a acoperirii conexe, scrisă pentru aiqbench. Nu sunt cuvintele publicației.

Machine Learning for Pre-Culture ESBL Risk Stratification to Guide Empiric Antibiotic Selection: A 12-Hospital Study of Enterobacteriaceae Cultures

arXiv2 min de cititArticolul și perspectiva sunt în engleză.

arXiv:2609.05970v1 Announce Type: new Abstract: Empiric antibiotic therapy for suspected ESBL-producing Enterobacteriaceae must be selected 48-72 hours before culture results, forcing clinicians to choose between undertreating resistant infections and overusing carbapenems that drive further resistance. We developed a cost-sensitive XGBoost model predicting an ESBL phenotype (resistance to ceftriaxone, ceftazidime, cefepime or piperacillin-tazobactam) at culture ordering using 45 pre-culture EHR features across 132,955 cultures from 72,217 patients at 12 hospitals (14.41% with the ESBL phenotype). Cultures were partitioned at the patient level. At 90% sensitivity, the model achieved 95.8% NPV, reducing post-test ESBL probability to 4.2%, a threshold that may support safe carbapenem-sparing in non-ICU settings, while sparing 307 of every 1,000 cultures an unnecessary broad-spectrum course at the cost of 14 missed ESBL cases per 1,000. SHAP analysis identified prior ESBL colonization as the dominant predictor, ahead of prior organism burden and neighborhood deprivation; removing deprivation features caused minimal performance loss ($\Delta\text{AUROC} = -0.020$), enabling equitable bedside deployment. Discrimination was unchanged under a strict IDSA ESBL-E definition (AUROC 0.766), with specimen type added as a predictor (0.764) and without any class-imbalance correction (0.762), and ranged from 0.71 to 0.78 across organism strata.

Abstract:Empiric antibiotic therapy for suspected ESBL-producing Enterobacteriaceae must be selected 48-72 hours before culture results, forcing clinicians to choose between undertreating resistant infections and overusing carbapenems that drive further resistance. We developed a cost-sensitive XGBoost model predicting an ESBL phenotype (resistance to ceftriaxone, ceftazidime, cefepime or piperacillin-tazobactam) at culture ordering using 45 pre-culture EHR features across 132,955 cultures from 72,217 patients at 12 hospitals (14.41% with the ESBL phenotype). Cultures were partitioned at the patient level. At 90% sensitivity, the model achieved 95.8% NPV, reducing post-test ESBL probability to 4.2%, a threshold that may support safe carbapenem-sparing in non-ICU settings, while sparing 307 of every 1,000 cultures an unnecessary broad-spectrum course at the cost of 14 missed ESBL cases per 1,000. SHAP analysis identified prior ESBL colonization as the dominant predictor, ahead of prior organism burden and neighborhood deprivation; removing deprivation features caused minimal performance loss ($\Delta\text{AUROC} = -0.020$), enabling equitable bedside deployment. Discrimination was unchanged under a strict IDSA ESBL-E definition (AUROC 0.766), with specimen type added as a predictor (0.764) and without any class-imbalance correction (0.762), and ranged from 0.71 to 0.78 across organism strata.

Machine Learning (cs.LG); Applications (stat.AP)

arXiv:2609.05970 [cs.LG]

(or arXiv:2609.05970v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2609.05970 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Text integral sub licența deschisă a publicației · 283 cuvinte

Subiecte conexe